Login to Your Account



Celera Could Get $365M For Selling Cathepsin S Program

By Karen Pihl-Carey


Thursday, June 22, 2006
Completing its planned exit from small-molecule development, Celera Genomics sold its cathepsin S inhibitor program to Schering AG in a deal worth up to $365 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription